Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Metronomic capecitabine combined with aromatase inhibitors for new chemoendocrine treatment of advanced breast cancer: a phase II clinical trial
Authors
Keywords
-
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume -, Issue -, Pages -
Publisher
Springer Nature America, Inc
Online
2018-10-25
DOI
10.1007/s10549-018-5024-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and Safety of Vinorelbine-Capecitabine Oral Metronomic Combination in Elderly Metastatic Breast Cancer Patients: VICTOR-1 Study
- (2017) Marina E. Cazzaniga et al. TUMORI
- Efficacy and Safety of Vinorelbine-Capecitabine Oral Metronomic Combination in Elderly Metastatic Breast Cancer Patients: VICTOR-1 Study
- (2017) Marina E. Cazzaniga et al. TUMORI JOURNAL
- The efficacy and toxicity profile of metronomic chemotherapy for metastatic breast cancer: A meta-analysis
- (2017) Yangyang Liu et al. PLoS One
- Metronomic chemotherapy for triple negative breast cancer?
- (2016) Teresa Di Desidero et al. Aging-US
- Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study
- (2016) M. E. Cazzaniga et al. BREAST CANCER RESEARCH AND TREATMENT
- Metronomic Chemotherapy for Metastatic Breast Cancer – a Systematic Review of the Literature
- (2016) M. Banys-Paluchowski et al. GEBURTSHILFE UND FRAUENHEILKUNDE
- Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial
- (2016) Richard G Margolese et al. LANCET
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- Metronomic chemotherapy from rationale to clinical studies: A dream or reality?
- (2015) Antonio Gnoni et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study
- (2014) Alfredo Berruti et al. BMC CANCER
- A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer
- (2014) N. Masuda et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Metronomic therapy and breast cancer: A systematic review
- (2014) Emilia Montagna et al. CANCER TREATMENT REVIEWS
- Phase II Trial of Fulvestrant With Metronomic Capecitabine for Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
- (2013) Lee S. Schwartzberg et al. Clinical Breast Cancer
- The sequential use of endocrine treatment for advanced breast cancer: where are we?
- (2012) C. Barrios et al. ANNALS OF ONCOLOGY
- Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer
- (2012) Masataka Yoshimoto et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase ii trial of a metronomic schedule of docetaxel and capecitabine with concurrent celecoxib in patients with prior anthracycline exposure for metastatic breast cancer
- (2012) S.D. Young et al. Current Oncology
- Concurrent vs Sequential Adjuvant Chemotherapy and Hormone Therapy in Breast Cancer: A Multicenter Randomized Phase III Trial
- (2011) Davide Bedognetti et al. JNCI-Journal of the National Cancer Institute
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts
- (2011) Yoichiro Moriya ONCOLOGY REPORTS
- Unfavourable clinicopathologic features and low response rate to systemic adjuvant therapy: results with regard to poor survival in young Chinese breast cancer patients
- (2009) Li-Chen Tang et al. BREAST CANCER RESEARCH AND TREATMENT
- Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial
- (2009) Kathy S Albain et al. LANCET
- Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer
- (2008) Silvia Dellapasqua et al. JOURNAL OF CLINICAL ONCOLOGY
- Combining endocrine agents with chemotherapy: Which patients and what sequence?
- (2007) Kathleen I. Pritchard CANCER
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started